| 1 |
钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
|
| 2 |
房延凤，马李杰，刘雁声，等. 非小细胞肺癌E19-Del、L858R突变临床特征分析[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(2): 164-168.
|
| 3 |
Jonna S, Subramaniam DS. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update[J]. Discov Med, 2019, 27(148): 167-170.
|
| 4 |
Liao WC, Huang BS, Yu YH, et al. Galectin-3 and S100A9: Novel diabetogenic factors mediating pancreatic cancer-associated diabetes[J]. Diabetes Care, 2019, 42(9): 1752-1759.
|
| 5 |
Li C, Chen Q, Zhou Y, et al. S100A2 promotes glycolysis and proliferation via GLUT1 regulation in colorectal cancer[J]. FASEB J, 2020, 34(10): 13333-13344.
|
| 6 |
Sun J, Ambrus JI, Russell CC, et al. Targeting the S100A2-p53 interaction with a series of 3，5-bis(trifluoromethyl)benzene sulfonamides: synthesis and cytotoxicity[J]. Chem Med Chem, 2021, 16(18): 2851-2863.
|
| 7 |
王书航，王 洁. 2018年V3版NCCN非小细胞肺癌指南更新要点解读[J]. 华西医学，2018, 33(4): 388-392.
|
| 8 |
Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review[J]. JAMA, 2019, 322(8): 764-774.
|
| 9 |
郭涛弦，范红松，罗 勤. 非小细胞肺癌患者血清S100A8, S100A9, MMP-9的表达及意义[J]. 国际呼吸杂志，2020, 40(22): 1729-1734.
|
| 10 |
Pennell NA, Arcila ME, Gandara DR, et al. Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices[J]. Am Soc Clin Oncol Educ Book, 2019, 39(25): 531-542.
|
| 11 |
Tan AC. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC)[J]. Thorac Cancer, 2020, 11(3): 511-518.
|
| 12 |
She C, Wang R, Lu C, et al. Prognostic factors and outcome of surgically treated patients with brain metastases of non-small cell lung cancer[J]. Thorac Cancer, 2019, 10(2): 137-142.
|
| 13 |
Hu ZG, Hu K, Li WX, et al. Prognostic factors and nomogram for cancer-specific death in non small cell lung cancer with malignant pericardial effusion[J]. PLoS One, 2019, 14(5): 72-75.
|
| 14 |
Endo M, Shiono S, Suzuki K, et al. Long-term outcome of pulmonary segmentectomy for lung cancer[J]. Kyobu Geka, 2019, 72(7): 543-549.
|
| 15 |
Zha H, Li X, Sun H, et al. S100A9 promotes the proliferation and migration of cervical cancer cells by inducing epithelial mesenchymal transition and activating the Wnt/β catenin pathway[J]. Int J Oncol, 2019, 55(1): 35-44.
|
| 16 |
Wang H, Hu X, Yang F, et al. miR-325-3p promotes the proliferation，invasion, and EMT of breast cancer cells by directly targeting S100A2[J]. Oncol Res, 2021, 28(7): 731-744.
|
| 17 |
Zhao Z, Zhang C, Zhao Q. S100A9 as a novel diagnostic and prognostic biomarker in human gastric cancer[J]. Scand J Gastroenterol, 2020, 55(3): 338-346.
|
| 18 |
寇晓桂，陈葆青. S100A2检测在非小细胞肺癌并发胸腔积液诊断中的价值[J]. 陕西医学杂志，2018, 47(6): 745-747.
|